growth hormone

Low-dose growth hormone therapy reduces inflammation in HIV-infected patients

Randomized controlled trial Lindboe JB, et al. Infect Dis (Lond). 2016 Nov-Dec. Authors Lindboe JB1, Langkilde A1, Eugen-Olsen J2, Hansen BR2,3, Haupt TH1, Petersen J1,4, Andersen O1,3. Author information 1a Optimed, Clinical Research Centre 056, Copenhagen University Hospital Hvidovre , Hvidovre , Denmark ; 2b Clinical Research Centre 056, Copenhagen University Hospital Hvidovre , Hvidovre …

Low-dose growth hormone therapy reduces inflammation in HIV-infected patients Read More »

Complementary Approaches to Treating Lipodystrophy

From the book: Built to Survive 12.  Complementary Approaches to Treating Lipodystrophy By Michael Mooney (original version in Medibolics 2(2),Nov. 1997) While the protease inhibitor (PI) cocktails can bring viral loads down to undetectable levels and have given many HIV(+) people a new lease on life, protease inhibitors are not always benign drugs. As we approach year …

Complementary Approaches to Treating Lipodystrophy Read More »

Update on Egrifta for the reduction of visceral fat accumulation associated with HIV lpodystrophy

Serono launched Egrifta this month. Doctors are calling in the number included in the link below to get the paper work started for insurance reimbursement. It seems that some insurance companies are  already starting to pay for it, but high copays may be required. Serono has a $200 copay assistance per prescription. The total yearly …

Update on Egrifta for the reduction of visceral fat accumulation associated with HIV lpodystrophy Read More »

FDA Committee Unanimously Recommends Egrifta for Lipodystrophy

FROM POZ.COM May 27, 2010 FDA Committee Unanimously Recommends Egrifta for Lipodystrophy A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended that Egrifta (tesamorelin), Montreal-based Theratechnologies’ experimental product for the treatment of excess abdominal fat in HIV-positive people with lipodystrophy, be approved by the agency.  Though the FDA is not required to …

FDA Committee Unanimously Recommends Egrifta for Lipodystrophy Read More »

An Anti-frailty Pill For Seniors? New Drug Increases Muscle Mass In Arms And Legs Of Older Adults

I bet this could compete with Theratecnologies/Serono’s Tesamorelin eventually. But Merck is smart going after baby aging boomers An Anti-frailty Pill For Seniors? New Drug Increases Muscle Mass In Arms And Legs Of Older AdultsScienceDaily (Nov. 5, 2008) — Researchers at the University of Virginia Health System report that a daily single oral dose of …

An Anti-frailty Pill For Seniors? New Drug Increases Muscle Mass In Arms And Legs Of Older Adults Read More »